Table 2.

Treatment details and responses

Patient	Sex	Time from Initial Diagnosis to Liver Metastases, mo	Time from Diagnosis of Liver Metastases to Radioembolization, mo	Microsphere Delivered Activity, GBq	AEs	Best Liver Response	Duration of Response in Liver, mo	Best Overall Response	Subsequent Therapy	Best Response To Subsequent Therapy
1	F	45	4	1.8	G1 fatigue	PD	1	PD	Nil
2	M	17	1	1.7	G1 nausea G1 abdominal pain	SD	9	SD	Pembrolizumab Ipilimumabb	PD
3	F	24	3	1.42	G1 abdominal pain	PR	29	PR	Pembrolizumab	PD
4	M	59	67	1.8	G2 abdominal pain	PR	9	PR	Pembrolizumab	PD
5	M	8	3	1.65	G1 abdominal pain	PR	3	PDa	Pembrolizumab	PD
6	M	14	1	2.3	G2 fatigue G2 anorexia G2 abdominal pain	PD	1	PD	Pembrolizumab	PD
7	F	40	8	2.0	G1 fatigue	PD	3	PD	Nivolumabb Trametinib	PD
8	F	98	2	2.5	G1 fatigue G1 anorexia	SD	3	PDa	Nil
9	F	7	3	1.65	Nil	SD	6	SD	Pembrolizumab	NE
10	M	109	3	Nil		Nil	0	Nil	Nil

Abbreviations: AE, adverse event; G, grade; NE, not evaluable; PD, progressive disease; PR, partial response; SD, stable disease.

^aExtrahepatic disease progression despite ongoing intrahepatic disease control.

^bSequential treatment.